# US 2013/0251641 A1 · Functionalized Magnetic Nanoparticles and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251641 A1
- Document ID: US20130251641A1
- Status: Published application
- Kind: A1
- Application number: 13/784,343
- Filed: 2013-03-04
- Published: 2013-09-26
- Earliest claimed: 2008-04-04
- Assignees: The Regents of the Universtiy of California
- Applicants: The Regents of the University of California
- Inventors: MASSOUD AKHTARI; JEROME ENGEL
- Web page: https://patentgrep.com/patent/US20130251641A1

## CPC

- A61K 49/10: Organic compounds
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 49/085: {conjugated systems}
- A61K 49/1845: {the small organic molecule being a carbohydrate (monosaccharides, discacharides)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present disclosure provides compositions comprising 2-deoxyglucose-functionalized magnetic nanoparticles. The compositions are useful in various applications, which are also provided.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a) a functionalized magnetic nanoparticle (MNP) comprising at least one functional moiety, wherein the at least one functional moiety comprises 2-deoxyglucose, and wherein the functionalized MNP exhibits differential affinity and/or metabolic uptake into a mammalian tissue;
wherein the magnetic nanoparticle comprises a magnetic core particle and a biocompatible substrate, and wherein the 2DG is linked to the biocompatible substrate;
wherein the 2DG is linked to the biocompatible substrate via the 1-OH oxygen, the 3-OH oxygen, the 4-OH oxygen of 2DG, or via a carbon atom of 2DG; and
b) a pharmaceutically acceptable carrier.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The composition of claim 1, wherein the biocompatible substrate is dextran, an iron-dextran complex, a polysaccharide, polyethylene glycol, a polyethylene oxide, starch, a phospholipid, a poloxamer, a poloxamine, a silicone, a polyvinyl alcohol, or albumin.

### Claim at position 4

4-6. (canceled)

### Claim 7 (depends on 1)

The composition of claim 1, wherein the functionalized MNP has a diameter of from about 10 nm to about 300 nm.

### Claim 8 (depends on 1)

The composition of claim 1, wherein said functionalized magnetic nanoparticle is capable, when injected into the bloodstream of a mammalian subject, of crossing the blood-brain barrier of said subject.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the tissue is a diseased tissue.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the level of metabolic uptake of the functionalized MNP by the diseased tissue is less than the level of metabolic uptake of the functionalized MNP by normal tissue.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the diseased tissue is a plaque associated with Alzheimer's Disease, a tissue affected by Huntington's Disease, a tissue affected by Parkinson's Disease, a diseased cardiac tissue, a tissue affected by amyotrophic lateral sclerosis.

### Claim 12 (depends on 9)

The composition of claim 9, wherein the level of metabolic uptake of the functionalized MNP by the diseased tissue is greater than the level of metabolic uptake of the functionalized MNP by normal tissue.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the tissue is a cancerous tissue.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the tissue is an epileptigenic tissue.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the functionalize MNP comprises at least a second functional moiety.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the second functional moiety comprises a therapeutic agent.

### Claim 17 (depends on 1)

A method of detecting a tissue in a living mammalian subject, the method comprising
a) administering to a mammalian subject a composition according to claim 1, wherein the functionalized MNP exhibits differential affinity for, and/or metabolic uptake into, a tissue in the mammalian subject; and
b) detecting the presence of the functionalized MNP in association with the tissue.

### Claim 18 (depends on 17)

The method of claim 17, wherein the tissue is a diseased tissue.

### Claim 19 (depends on 18)

The method of claim 18, wherein the level of metabolic uptake of the functionalized MNP by the diseased tissue is less than the level of metabolic uptake of the functionalized MNP by normal tissue.

### Claim 20 (depends on 19)

The method of claim 19, wherein the diseased tissue is a plaque associated with Alzheimer's Disease, a tissue affected by Huntington's Disease, a tissue affected by Parkinson's Disease, a diseased cardiac tissue, and a tissue affected by amyotrophic lateral sclerosis.

### Claim 21 (depends on 18)

The method of claim 18, wherein the level of metabolic uptake of the functionalized MNP by the diseased tissue is greater than the level of metabolic uptake of the functionalized MNP by normal tissue.

### Claim 22 (depends on 21)

The method of claim 21, wherein the tissue is a cancerous tissue or an epileptic lesion.

### Claim 23

(canceled)

### Claim 24 (depends on 17)

The method of claim 17, wherein the functionalized MNP further comprises at least a second functional moiety.

### Claim 25 (depends on 24)

The method of claim 24, wherein the second functional moiety comprises a therapeutic agent.

### Claim 26 (depends on 17)

The method of claim 17, wherein said detecting comprises magnetic resonance imaging or computed tomography.

### Claim 27

(canceled)

### Claim 28 (depends on 16)

A method of treating a disease in an individual, the method comprising administering a composition according to claim 16 to the individual, wherein the functionalized MNP exhibits differential affinity for, and/or differential metabolic uptake into, a diseased tissue associated with the disease, and wherein the therapeutic agent treats the disease.

### Claim 29 (depends on 28)

The method of claim 28, wherein the diseased tissue is an epileptic lesion, and the therapeutic agent is an anti-seizure agent.

### Claim 30 (depends on 28)

The method of claim 28, wherein the diseased tissue is a tissue affected by Parkinson's Disease, and wherein the therapeutic agent is L-DOPA.

### Claim 31 (depends on 30)

The method of claim 30, wherein the diseased tissue is a tissue affected by Alzheimer's Disease, and wherein the therapeutic agent is donepezil HCl, rivastigmine, galantamine, memantine, or tacrine.

### Claim 32 (depends on 28)

The method of claim 28, wherein the diseased tissue is a cancerous tissue, and the therapeutic agent is an anti-cancer agent.

### Claim at position 31

33-35. (canceled)
